CONCLUSIONS: We used current, nationally representative, population-based, data to demonstrate that the rate of post-prostate biopsy infectious complications continues to increase. Although it is beyond the scope of our study design to assign a reason for this sustained increase, our findings call for an urgent need to identify strategies to effectively combat infectious complications. METHODS: A comprehensive literature search was conducted in July 2018 in Ovid MEDLINE, Ovid EMBASE and Cochrane Library using predefined inclusion/exclusion criteria. Independent reviewers (MG and MA) screened a total of 2898 records and reviewed 49 full texts. Eight studies were included in our final meta-analysis. All doublearm comparative studies, including randomized-controlled trials and cohort studies, reporting the infectious complication rates following prostate biopsy were included. All TP biopsies were performed under general anesthesia. Meta-analysis was performed using the MantelHaenszel Method and Dersimonian-Laird estimator for € I"2. Heterogeneity was analyzed using the Cochrane Q and I2 tests.
INTRODUCTION AND OBJECTIVES:
The risk of prostate needle biopsy (PNBx) infections and sepsis is increasing, with recent estimates of 7% and 3%, respectively. Each post-PNBx infection costs an estimated $5,800 per event. With 165,000 incident prostate cancers annually in the US and greater use of active surveillance, there is greater need for strategies to decrease post-PNBx infections. We performed a meta-analysis with contemporary evidence to evaluate transrectal (TR) vs. transperineal (TP) PNBx infections to determine the importance of biopsy approach.
METHODS: A comprehensive literature search was conducted in July 2018 in Ovid MEDLINE, Ovid EMBASE and Cochrane Library using predefined inclusion/exclusion criteria. Independent reviewers (MG and MA) screened a total of 2898 records and reviewed 49 full texts. Eight studies were included in our final meta-analysis. All doublearm comparative studies, including randomized-controlled trials and cohort studies, reporting the infectious complication rates following prostate biopsy were included. All TP biopsies were performed under general anesthesia. Meta-analysis was performed using the MantelHaenszel Method and Dersimonian-Laird estimator for € I"2. Heterogeneity was analyzed using the Cochrane Q and I2 tests.
RESULTS: TR PNBx was associated with higher odds for infection (Figure 1) (Figure 2) .
CONCLUSIONS: The meta-analysis demonstrates that TR versus TP PNBx was associated with more than three times higher odds ratio for infectious complications. Our findings may guide the adoption of targeted biopsy and in-office TP approaches, which currently lacks comparative evidence.
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Evert Baten, Kessel-lo, Belgium; Ingrid Arijs, Hasselt, Belgium; Hans Goethuys, Genk, Belgium; Machteld Vandecandelaere, Herent, Belgium; Reinout Cartuyvels, Hasselt, Belgium; Frank Van der Aa, Leuven, Belgium; Koenraad van Renterghem, Hasselt, Belgium; Thomas Van den Broeck*, Leuven, Belgium INTRODUCTION AND OBJECTIVES: Microbial resistance is an increasing problem in healthcare and antibiotic use should be minimized whenever possible. The guidelines recommend antimicrobial prophylaxis (AMP) in TURP but are mainly based on dated literature. Our study was set up to investigate the current value of AMP in a prospective, multi-centered randomized controlled-trial (RCT). METHODS: After approval by the ethical committee (B243201733480) a prospective RCT was initiated in 5 hospitals starting from 17 September 2017 to compare AMP vs control in TURP. A power analysis was performed (alpha 0.05 and power 80%) and an inclusion of 556 patients is scheduled in a 1:1 randomization. Exclusion criteria for the study are a pre-operative catheter or pre-operative pyuria > 100 white blood-cells/µL (WBC). Primary endpoint are uncomplicated (< 38.5 C) or complicated (>38.5 C or urosepsis) post-operative urinary tract infection (UTI). Secondary endpoints are post-operative bacteriuria (>105 micro-organisms) at time of hospital discharge and after 4 weeks at the follow-up consultation.
RESULTS: 304 patients are already included since 17 September 2017. Mean pre-op age was 69.8, mean PSA 5 ng/mL and mean prostate volume 55 g. 24/304 (8.2%) Patients have DM-2, 44/304 (14.5%) had a pre-operative cystoscopy and 21/304 (6.5%) urodynamics. Mean operating time 48.9 minutes for a mean resected prostate volume of 26.4 g. Pathology showed active prostatitis in 22/ 304 (7.2%), chronic prostatitis in 15/304 (4.9%), malignancy in 53/304
